ArticlePloS one2025
Validation of retroactively derived T1 relaxation values from 3D T1-weighted images with clinical and MRI measures of disability in multiple sclerosis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundQuantitative T1 mapping is a valuable technique for assessing tissue injury in multiple sclerosis (MS) lesions. We previously introduced a novel methodology for converting high-resolution anatomical 3D T1-weighted (T1W) images into parametric T1 relaxometry maps. Herein, we correlate MS lesion pathology as quantified by retroactive T1 mapping with clinical and MRI metrics of disability and with magnetization transfer ratio (MTR).
methods38 subjects with relapsing-remitting MS (RRMS) were examined, contributing to 587 unique lesions for analysis. T1 and MTR values were compared using correlation statistics. Univariate correlations between lesional T1 or MTR and Expanded Disability Status Scale (EDSS) were examined using Spearman's rho (ρ), and for disease duration and brain parenchymal fraction (BPF), Pearson's r. Mean T1 values of lesions were compared across different categories of EDSS severity using Kruskal-Wallis test. Ordinal regression model was used to assess the association between EDSS and T1 values of select brain regions.
resultsThe mean T1 of lesions showed a high correlation with - MTR, r = 0.68. T2 lesion volumes stratified based on different T1 thresholds showed a significant correlation with MS disease metrics: lesion volume threshold at 700 < T1 < 900 was correlated with disease duration (r = 0.34, p = 0.04) and BPF (r = -0.47, p = 0.003); lesion volume threshold at 900 < T1 < 1100 was correlated with EDSS (ρ = 0.42, p = 0.01), disease duration (r = 0.45, p = 0.01), and BPF (r = -0.56, p < 0.001); lesion volume threshold at T1 > 1100 was correlated with EDSS (ρ = 0.41, p = 0.01), disease duration (r = 0.45, p = 0.001), and BPF (r = -0.51, p < 0.001). T1 values at the 25th, 50th, and 75th percentiles significantly correlated with BPF (r = -0.41, p = 0.01; r = -0.41, p = 0.01; r = -0.38, p = 0.02). MTR showed a significant correlation with EDSS but not with disease duration or BPF. Mean T1 values in the NAWM showed a significant association with EDSS (coefficient = 0.03, pseudo R2 = 0.07, p = 0.03).
conclusionsWe provide clinical validation of retroactive T1 mapping as a complementary post-processing technique for monitoring disease activity and disability progression in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.